Hepatocellular carcinoma (HCC) is one of the most common causes of cancer‐related
deaths globally due, in part, to the majority of patients being diagnosed with intermediate or …

Hepatocellular carcinoma (HCC) is one of the main cancer-related causes of death
worldwide. Thus, there is a constant search for improvement in screening, diagnosis, and …

Purpose: Atezolizumab+ bevacizumab is the new standard of care for systemic treatment-
naive, unresectable hepatocellular carcinoma (HCC). This exploratory study investigated on …

Hepatocellular carcinoma (HCC), the most common primary liver tumor, is notoriously
resistant to systemic therapies, and often recurs even after aggressive local therapies. HCCs …

Sorafenib has been considered the standard of care for patients with advanced
unresectable hepatocellular carcinoma (HCC) since 2007 and numerous studies have …

Sorafenib is the first-line treatment of advanced hepatocellular carcinoma (HCC). However,
there is a lack of validated biomarkers to predict sorafenib sensitivity. In this study we …

Over the past decade, immune checkpoint blockade (ICB) therapy has revolutionized the
outlook for oncology with significant and sustained improvement in the overall patient …

Background The approval of the tyrosine kinase inhibitor sorafenib in 2007 marked a
milestone in the treatment of hepatocellular carcinoma, as sorafenib was the first systemic …

Current imaging technologies do not sufficiently detect micrometastasis and therefore do not
allow adequate stratification of patients with hepatocellular carcinoma (HCC) for curative or …

BACKGROUND: A significant improvement in overall survival (OS) was demonstrated in
patients with advanced hepatocellular carcinoma (HCC) who received sorafenib (Sor) in the …